Published: 11.07.2026 at 08:30 AM,
Editorial boerse-global.de
Recent medical research increasingly emphasizes nutrition and microbiome therapies for chronic inflammatory bowel diseases. Recent studies from Stanford Medicine and Tufts University offer promising results.
Fasting Protocols Alleviate Symptoms
Structured fasting periods significantly impact mild to moderate Crohn’s disease. A study from Stanford Medicine in Nature Medicine explored a monthly five-day fasting protocol. About two-thirds of participants reported notable symptom relief, while clinically relevant inflammatory markers in stool decreased as well.
Time-restricted eating (16:8 model) also shows effects. Approximately two-thirds of patients benefited from this monthly dietary adjustment. Pilot studies suggest positive effects on comorbid conditions such as periodontitis.
Personalized Nutrition Reduces Hospital Stays
Individually tailored meal plans can reduce hospital admissions for inflammatory bowel disease patients by up to 31%. This is supported by data from Tufts University. Emergency room visits also decreased by around 20%.
At the heart of this strategy is the 30-Plants Formula: patients consume 30 different plant-based foods weekly, promoting microbiome diversity. The health company Fresenius has launched a specialized innovation center for nutritional therapies to develop market-ready solutions.
The Role of Genetics and Wearables as Early Warning Systems
Diagnostics are becoming increasingly precise. Researchers have identified a four-gene signature with a diagnostic accuracy of over 96%. The biomarker HLA-DRB1*01:03 is associated with an increased risk of colon resections. Autoantibodies against interleukin-10 are also considered potential markers.
Smartwatches and fitness trackers may soon predict disease flare-ups. Notably, monitoring REM sleep provides valuable data.
Phage Therapy: Viruses Against Inflammation
A new approach combats inflammation-causing bacteria. A study in Science Translational Medicine describes the bacteriophage HER259. It deactivates the fimS region of adherent-invasive Escherichia coli (AIEC), which is common in Crohn’s disease patients.
In mouse models, HER259 reduced the inflammatory response in the gut. The combination with the glucocorticoid Budesonide was particularly effective, enhancing the drug’s action. However, experts emphasize that continuous administration is necessary for long-term success.
Fasting Regenerates the Gut Flora
The MD Anderson Cancer Center is researching the regenerative power of fasting. A 24-hour fast led to an increase in the bacterium Akkermansia muciniphila, which produces propionate and promotes the recovery of gut tissue damaged by radiation or inflammation.
Disclaimer: No investment advice, no buy or sell recommendations. Information regarding prices, companies, and markets may be subject to change; please verify before acting. Trading can lead to significant losses. Our articles are created and reviewed, partially automated, with the assistance of AI.
